High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. V. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP1A2 inhibition assessment

European Journal of Pharmaceutical Sciences

Volumn 12, Issue 4, 2001, Pages 447-452

  Bu, Hai Zhi ^a   Knuth, Kim ^a   Magis, Lisa ^a   Teitelbaum, Philip ^a  

^a 206 Carnegie Center   (United States)

Author keywords

CYP1A2; Direct injection; High throughput; Inhibition; On line extraction

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; ETHOXYRESORUFIN; FURAFYLLINE; KETOCONAZOLE; PHENACETIN; QUINIDINE; RESORUFIN;

ACCURACY; ARTICLE; CALIBRATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACTION; HUMAN; HUMAN CELL; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL; SCREENING; TANDEM MASS SPECTROMETRY;

BENZOFLAVONES; BIOLOGICAL ASSAY; CYTOCHROME P-450 CYP1A2; ENZYME INHIBITORS; HUMANS; MASS SPECTROMETRY; MICROSOMES, LIVER; OXAZINES; THEOPHYLLINE;

EID: 0035108902     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(00)00190-1     Document Type: Article

References (23)

1. Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples
2. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes
3. High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy: I. Development of direct injection/on-line guard cartridge extraction/tandem mass spectrometry for the simultaneous detection of CYP probe substrates and their metabolites
4. High-throughput Caco-2 cell permeability screening by cassette dosing and sample pooling approaches using direct injection/on-line guard cartridge extraction/tandem mass spectrometry
5. In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse
6. Inducibility and expression of class IA and IIIA cytochromes P450 in primary cultures of adult human hepatocytes
7. Validation of the five-drug 'Pittsburgh cocktail' approach for assessment of selective regulation of drug-metabolizing enzymes
8. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells
9. Role of pharmacokinetics and metabolism in drug discovery and development
10. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential
11. Biotransformation of xenobiotics
12. Cellular localization of hepatic cytochrome 1B1 expression and its regulation by aromatic hydrocarbons and inflammatory cytokines
13. Expression of CYP1A1 and CYP1A2 genes in human liver
14. Determination of a 'GW cocktail' of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry
15. Furafylline is potent and selective inhibitor of cytochrome P450IA2 in man
16. Differential expression and regulation of members of the cytochrome P450IA gene subfamily in human tissues
17. Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons
18. Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens
19. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals
20. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1
21. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1
22. Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2
23. Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation